REGN250110P580000
- 2.28
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Nation's Top 300 Teen Scientists Selected for Achievements in STEM Innovation and Leadership in Nation's Oldest and Most Prestigious High School Competition
Wednesday MArket Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
The Easy Money Has Been Made in Options. What to Do Now.
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,004
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Regeneron Pharmaceuticals Analyst Ratings
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,184
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,070
Express News | Regeneron Pharmaceuticals Inc : Bernstein Cuts Target Price to $1070 From $1110
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Regeneron Expands Eye Care Focus With Oxular Buyout
Santa Claus Came Without Rallying the Troops | Live Stock
Regeneron Pharmaceuticals' (NASDAQ:REGN) Investors Will Be Pleased With Their Decent 89% Return Over the Last Five Years
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock